Legemidler (11941)

This tender for pharmaceutical products presents a moderate opportunity for established suppliers. The key to winning lies in demonstrating robust supply chain reliability, competitive pricing, and a strong commitment to green procurement, despite the absence of explicit social or innovative aspects. A proactive approach to understanding and addressing unstated evaluation criteria will be crucial.

Reliable and Sustainable Pharmaceutical Supply Chain Partner for Santaros Klinikos.

Cost-Effective and Environmentally Conscious Pharmaceutical Solutions.

Offer highly competitive pricing, supported by efficient supply chain management and economies of scale. Benchmark against market rates for similar products.

Detail specific initiatives for reducing carbon footprint in transportation, sustainable packaging solutions, and waste management. Quantify environmental benefits where possible.

Provide robust evidence of delivery performance, inventory management systems, and contingency plans to ensure consistent supply throughout the 26-month duration.

Despite AI summaries being incomplete, meticulously review all provided documents (BPS.docx, espd-request.pdf, etc.) for any hidden requirements, specifications, or context that could inform the bid strategy. Pay close attention to any annexes or appendices.

Given the absence of explicit evaluation criteria, research typical weighting for price, quality, delivery, and green procurement in similar public tenders in Lithuania. Structure the bid to excel in these inferred areas, prioritizing price competitiveness and demonstrable green procurement efforts.

Go beyond basic compliance. Detail specific, measurable actions the bidder will take to meet and exceed green procurement goals, such as optimizing delivery routes, using eco-friendly packaging, and offering products with lower environmental impact. Quantify benefits where possible.

Given the 26-month duration and the critical nature of pharmaceutical supply, outline a comprehensive plan for ensuring uninterrupted delivery, including inventory management, supplier diversification, and contingency measures for disruptions (e.g., logistical challenges, stockouts).

While 'Social Aspects' are marked as 'No', integrate social value into the green procurement narrative. For example, highlight partnerships with local suppliers where feasible, or initiatives that support local employment within the supply chain, framing it as part of a sustainable business model.

If permissible by the tender rules, consider submitting clarifying questions to the contracting authority regarding the lack of specified technical, financial, or evaluation criteria. Frame questions constructively to gain insight without revealing strategic intent.

With no explicit technical differentiation, price will likely be a significant factor. Conduct thorough market analysis to ensure pricing is highly competitive, leveraging economies of scale and efficient operational costs.

This tender for pharmaceutical products is generally well-structured with clear basic information and available documents. However, it lacks specific details on evaluation criteria and technical/eligibility requirements, impacting clarity and completeness.

The tender adheres to general EU procurement directives (Code: 2014/24/ES) and uses a proper CPV code. Deadlines appear reasonable for an open procedure, and there are no immediate indications of disputes. The procedure is clearly defined as 'OPEN'.

The description of the procurement ('various pharmaceutical products') is concise. While essential documents like technical specifications and contract drafts are available, the absence of specified evaluation criteria and detailed eligibility/technical requirements leaves room for interpretation.

Most basic information is present, including estimated value, contract duration, and a submission deadline. However, the AI-extracted requirements section is largely empty, suggesting that detailed mandatory exclusion grounds, eligibility, technical, and financial requirements might be missing or not easily extractable from the provided documents.

The tender is an open procedure, promoting broad participation. Access to documents is implied through the list provided. The estimated value is disclosed, and criteria for evaluation are expected to be in the documents. There are no obvious signs of tailoring requirements to specific companies.

The tender is marked as 'E-Procurement', suggesting electronic submission is possible. However, the 'No e-submission' flag in the checks section contradicts this, creating ambiguity. The contract start date is not explicitly stated, and financing information is absent.

Key fields like title, reference, organization, value, and deadlines are populated. The status is 'active', and there are no reported disputes or suspensions. Dates are logically ordered.

There is no explicit mention of green procurement, social aspects, or innovation within the provided information. The tender is not flagged as EU funded.